[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc (CATX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 331,874
  • Shares Outstanding, K 114,046
  • Annual Sales, $ 880 K
  • Annual Income, $ -103,120 K
  • EBIT $ -120 M
  • EBITDA $ -119 M
  • 60-Month Beta 1.74
  • Price/Sales 380.58
  • Price/Cash Flow N/A
  • Price/Book 0.97

Options Overview Details

View History
  • Implied Volatility 155.02% (-42.46%)
  • Historical Volatility 67.46%
  • IV Percentile 18%
  • IV Rank 7.58%
  • IV High 1,031.38% on 09/30/25
  • IV Low 83.11% on 01/20/26
  • Expected Move (DTE 25) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 40
  • Volume Avg (30-Day) 421
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 8,860
  • Open Int (30-Day) 8,978
  • Expected Range 2.82 to 2.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.27
  • Number of Estimates 8
  • High Estimate $-0.23
  • Low Estimate $-0.29
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.82 unch
on 07/27/26
3.78 -25.40%
on 07/02/26
-0.22 (-7.24%)
since 06/26/26
3-Month
2.82 unch
on 07/27/26
4.34 -35.02%
on 05/27/26
-1.45 (-33.96%)
since 04/27/26
52-Week
1.96 +44.25%
on 11/21/25
6.16 -54.22%
on 01/29/26
-1.24 (-30.54%)
since 07/25/25

Most Recent Stories

More News
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...

CATX : 2.82 (-3.09%)
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...

CATX : 2.82 (-3.09%)
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...

CATX : 2.82 (-3.09%)
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

One new responder observed in the [ 212 Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated...

CATX : 2.82 (-3.09%)
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...

CATX : 2.82 (-3.09%)
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability Three clinical-stage oncology programs advancing across neuroendocrine...

CATX : 2.82 (-3.09%)
Perspective Therapeutics Reports Another Quarter Where the Science Matters More Than the Revenue

Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...

CATX : 2.82 (-3.09%)
Perspective Therapeutics Reports Another Quarter Where the Science Matters More Than the Revenue

Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...

CATX : 2.82 (-3.09%)
Perspective Therapeutics Reports Another Quarter Where the Science Matters More Than the Revenue

Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...

CATX : 2.82 (-3.09%)
Perspective Therapeutics to Provide Several Upcoming Corporate Updates

SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced...

CATX : 2.82 (-3.09%)

Business Summary

Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash....

See More

Key Turning Points

3rd Resistance Point 3.15
2nd Resistance Point 3.09
1st Resistance Point 2.95
Last Price 2.82
1st Support Level 2.75
2nd Support Level 2.69
3rd Support Level 2.55

See More

52-Week High 6.16
Fibonacci 61.8% 4.55
Fibonacci 50% 4.06
Fibonacci 38.2% 3.56
Last Price 2.82
52-Week Low 1.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.